NurExone Biologic

NurExone Biologic's approach rests so far on preclinical results and orphan designations. The company develops exosome-based therapies for central nervous system injuries, making mesenchymal stem cell-derived exosomes via proprietary processes; ExoPTEN combines them with PTEN-inhibiting siRNA, and brief preclinical spinal cord injury treatment was associated with neural regeneration and improved functional outcomes. The program holds FDA and EMA Orphan Drug Designations for acute spinal cord injury and completed a pre-IND meeting with the FDA.

Alongside its therapeutic work, NurExone Biologic develops exosome production and supply through Exo-Top, its wholly owned U.S. subsidiary. The company is listed on the TSX Venture Exchange, OTCQB and Frankfurt Stock Exchange and reports from Toronto and Haifa, Israel.